Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 10/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.70 |
| ▸ | NR3C1 | P04150 | 8/20 | 0.70 |
| ▸ | PGR | P06401 | 6/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.70 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.70 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.70 |
| ▸ | AR | P10275 | 2/20 | 0.70 |
| ▸ | TNF | P01375 | 1/20 | 0.70 |
| ▸ | IL6 | P05231 | 1/20 | 0.70 |
| ▸ | GLUL | P15104 | 1/20 | 0.70 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.70 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | SHBG | P04278 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13270299 | 0.99 | HIF1A (0.72) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| SCHEMBL1512721 | 0.99 | HIF1A (0.72) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| SCHEMBL2299293 | 0.99 | HIF1A (0.72) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| Phosphoric Acid SCHEMBL5501494 | 0.95 | NR3C1 (0.67) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| Succinic Acid SCHEMBL7600416 | 0.95 | HIF1A (0.66) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| Succinic Acid SCHEMBL7096415 | 0.94 | HIF1A (0.63) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| Phosphoric Acid SCHEMBL1237365 | 0.94 | NR3C1 (0.65) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| Succinic Acid SCHEMBL1477515 | 0.93 | HIF1A (0.64) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| Phosphoric Acid SCHEMBL1929804 | 0.93 | NR3C1 (0.64) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| Succinic Acid SCHEMBL40948 | 0.93 | HIF1A (0.64) | HIF1AHSD17B10NR3C1PGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11969432-B2 | Pharmaceutical composition and use thereof | BARNAS, ARIAN JANKUR CAN (AT) | 2024-04-30 | — | — | US | claimed |
| WO-2015074083-A1 | METHODS FOR DIAGNOSING T CELL-MEDIATED INFLAMMATION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-05-21 | — | — | WO | claimed |
| US-20150093434-A1 | LIPOSOMAL COMPOSITIONS OF GLUCOCORTICOID AND GLUCOCORTICOID DERIVATIVES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERSUSALEM (IL) | 2015-04-02 | — | — | US | claimed |
| US-8932627-B2 | Liposomal compositions of glucocorticoid and glucocorticoid derivatives | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2015-01-13 | — | — | US | claimed |
| US-7744920-B2 | Glucocoricoid is an amphipathic weak acid or base such as methylprednisolone sodium hemisuccinate encapsulated in a liposome; treating rheumatoid arthritis or other autoimmune disease, provided they are not neurodegenerative disorders | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2010-06-29 | — | — | US | claimed |
| US-20080058294-A1 | Glucocorticoid encapsulated within liposome; multiple sclerosis, anticancer agents | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2008-03-06 | — | — | US | claimed |
| US-20080003276-A1 | Glucocoricoid is an amphipathic weak acid or base such as methylprednisolone sodium hemisuccinate encapsulated in a liposome; treating rheumatoid arthritis or other autoimmune disease, provided they are not neurodegenerative disorders | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2008-01-03 | — | — | US | claimed |
| EP-1793804-A2 | USE OF LIPOSOMAL GLUCOCORTICOIDS FOR TREATING INFLAMMATORY STATES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-06-13 | — | — | EP | claimed |
| EP-1791525-A1 | LIPOSOMAL COMPOSITIONS OF GLUCOCORTICOID AND GLUCOCORTICOID DERIVATIVES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-06-06 | — | — | EP | claimed |
| EP-1512008-A4 | USE OF CORTICOTROPH-DERIVED GLYCOPROTEIN HORMONE TO TREAT INFLAMMATION AND POTENTIATE GLUCOCORTICOID ACTION | ZYMOGENETICS INC (US) | 2007-02-14 | — | — | EP | claimed |
| US-20070010446-A1 | METHODS FOR TREATING INFLAMMATION USING THYROID STIMULATING HORMONE | ZYMOGENETICS, INC. | 2007-01-11 | — | — | US | claimed |
| EP-1706138-A2 | METHODS FOR TREATING INFLAMMATION USING THYROID STIMULATING HORMONE | ZymoGenetics, Inc. (US) | 2006-10-04 | — | — | EP | claimed |
| WO-2006027787-A1 | LIPOSOMAL COMPOSITIONS OF GLUCOCORTICOID AND GLUCOCORTICOID DERIVATIVES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-03-16 | — | — | WO | claimed |
| WO-2006027786-A2 | USE OF LIPOSOMAL GLUCOCORTICOIDS FOR TREATING INFLAMMATORY STATES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-03-16 | — | — | WO | claimed |
| US-20050171017-A1 | Methods for treating inflammation using thyroid stimulating hormone | ZYMOGENETICS, INC. | 2005-08-04 | — | — | US | claimed |
| WO-2005056046-A2 | METHODS FOR TREATING INFLAMMATION USING THYROID STIMULATING HORMONE | ZYMOGENETICS, INC. (US) | 2005-06-23 | — | — | WO | claimed |
| EP-1512008-A1 | USE OF CORTICOTROPH-DERIVED GLYCOPROTEIN HORMONE TO TREAT INFLAMMATION AND POTENTIATE GLUCOCORTICOID ACTION | ZymoGenetics, Inc. (US) | 2005-03-09 | — | — | EP | claimed |
| US-20040138113-A1 | Use of corticotroph-derived glycoprotein hormone to treat inflammation and potentiate glucocorticoid action | ZYMOGENETICS, INC. | 2004-07-15 | — | — | US | claimed |
| WO-2003104807-A1 | USE OF CORTICOTROPH-DERIVED GLYCOPROTEIN HORMONE TO TREAT INFLAMMATION AND POTENTIATE GLUCOCORTICOID ACTION | ZYMOGENETICS, INC. (US) | 2003-12-18 | — | — | WO | claimed |
| US-20240156962-A1 | BCMA-TARGETED CAR-T CELL THERAPY OF MULTIPLE MYELOMA | LEGEND BIOTECH USA INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240156835-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS IN COMBINATION WITH GLUCOCORTICOIDS TO TREAT ADRENAL INSUFFICIENCY | CORCEPT THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| CN-118005799-A | Multispecific antibody molecules comprising lambda light chain and kappa light chain | 马伦戈治疗公司 | 2024-05-10 | — | — | CN | disclosed |
| WO-2024097738-A1 | BCMA-TARGETED CAR-T CELL THERAPY OF MULTIPLE MYELOMA | LEGEND BIOTECH USA INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-20240130980-A1 | COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS | Ilera Derm LLC | 2024-04-25 | — | — | US | disclosed |
| CN-111902146-B | Medicinal products for treating cough | 日本化学药品株式会社 | 2024-04-12 | — | — | CN | disclosed |
| US-11931452-B2 | Topical compositions containing rofecoxib and methods of making and using the same | JF PHARMA TECH LLC (US) | 2024-03-19 | — | — | US | disclosed |
| US-11890260-B2 | Compositions for treating acne and dermatological conditions | Ilera Derm LLC (US) | 2024-02-06 | — | — | US | disclosed |
| US-11890289-B2 | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency | CORCEPT THERAPEUTICS, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-11872313-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-01-16 | — | — | US | disclosed |
| US-20240000836-A1 | BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA | JANSSEN BIOTECH, INC. (US) | 2024-01-04 | — | — | US | disclosed |
| WO-2023246903-A1 | SELENIUM-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 暨南大学 | 2023-12-28 | — | — | WO | disclosed |
| US-20230270786-A1 | BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA | JANSSEN BIOTECH, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| CN-116510015-A | Compositions and methods for treating autoimmune diseases and cancers | 耶鲁大学 | 2023-08-01 | — | — | CN | disclosed |
| CN-116113411-A | Combined medicine for treating soft tissue sarcoma | 正大天晴药业集团股份有限公司 | 2023-05-12 | — | — | CN | disclosed |
| EP-4173620-A1 | BLOOD-CEREBROSPINAL FLUID BARRIER PROTECTING AGENT | National University Corporation Hokkaido University (JP) | 2023-05-03 | — | — | EP | disclosed |
| CN-115916183-A | Topical compositions containing rofecoxib and methods of making and using the same | 布里奥里生物技术公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-4153306-A1 | COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS | Ilera Derm LLC (US) | 2023-03-29 | — | — | EP | disclosed |
| CN-115843312-A | Multifunctional molecules that bind to T cell-associated cancer cells and uses thereof | 马伦戈治疗公司 | 2023-03-24 | — | — | CN | disclosed |
| US-20230025960-A1 | TOPICAL COMPOSITIONS CONTAINING ROSE OIL AND CANNABIDIOL AND METHODS OF MAKING AND USING THE SAME | JLABS Beauty LLC (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230001128-A1 | AEROSOLIZATION SYSTEMS, METHODS, AND APPARATUSES | SHUSTER GARY STEPHEN (CA) | 2023-01-05 | — | — | US | disclosed |
| WO-2022254337-A1 | CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | NOVARTIS AG (CH) | 2022-12-08 | — | — | WO | disclosed |
| US-20220168419-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCERS | YALE UNIVERSITY (US) | 2022-06-02 | — | — | US | disclosed |
| US-11260023-B2 | Topical compositions containing rofecoxib and methods of making and using the same | BRIORI BIOTECH, LLC (US) | 2022-03-01 | — | — | US | disclosed |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY INC (US) | 2022-02-10 | — | — | US | disclosed |
| EP-3277281-B1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS IN COMBINATION WITH GLUCOCORTICOIDS TO TREAT ADRENAL INSUFFICIENCY | CORCEPT THERAPEUTICS INC (US) | 2022-01-05 | — | — | EP | disclosed |
| WO-2021237214-A1 | COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS | Ilera Derm LLC (US) | 2021-11-25 | — | — | WO | disclosed |
| US-20210361591-A1 | COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS | Ilera Derm LLC | 2021-11-25 | — | — | US | disclosed |
| EP-3908243-A1 | POLYMER PROCESS BAGS AND METHODS FOR MANUFACTURING THE SAME | SiO2 Medical Products, Inc. (US) | 2021-11-17 | — | — | EP | disclosed |
| US-11141379-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2021-10-12 | — | — | US | disclosed |
| US-11123286-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| CN-113272281-A | ALK5 inhibitor for treating myelodysplastic syndrome | 大日本住友制药肿瘤公司 | 2021-08-17 | — | — | CN | disclosed |
| US-11084860-B2 | Modified Mullerian inhibiting substance (MIS) proteins and uses thereof for the treatment of diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2021-08-10 | — | — | US | disclosed |
| CN-108351344-B | Genome-scale T cell activity arrays and methods of use thereof | 耶鲁大学 | 2021-07-30 | — | — | CN | disclosed |
| US-20210220259-A1 | TOPICAL COMPOSITIONS CONTAINING ROFECOXIB AND METHODS OF MAKING AND USING THE SAME | ESTRATO PHARMA INC | 2021-07-22 | — | — | US | disclosed |
| WO-2021113083-A1 | TOPICAL COMPOSITIONS CONTAINING ROSE OIL AND CANNABIDIOL AND METHODS OF MAKING AND USING THE SAME | JLABS Beauty LLC (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20210169759-A1 | TOPICAL COMPOSITIONS CONTAINING ROSE OIL AND CANNABIDIOL AND METHODS OF MAKING AND USING THE SAME | JLABS Beauty LLC | 2021-06-10 | — | — | US | disclosed |
| WO-2021086879-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| EP-3806821-A1 | ORAL COMPOSITIONS COMPRISING METHYLPREDNISOLONE SODIUM SUCCINATE | Docu-Med Limited (CY) | 2021-04-21 | — | — | EP | disclosed |
| EP-3339294-B1 | QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER THEREOF AS AXL INHIBIOTOR | SHANGHAI HAIHE PHARMACEUTICAL CO LTD (CN) | 2021-04-14 | — | — | EP | disclosed |
| US-20210078972-A1 | QUINOLINE OR QUINAZOLINE COMPOUND AND APPLICATION THEREOF | JINAN UNIVERSITY (CN) | 2021-03-18 | — | — | US | disclosed |
| US-20210077400-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-03-18 | — | — | US | disclosed |
| US-20210059953-A1 | LIPID NANOPARTICLE FORMULATIONS OF NON-VIRAL, CAPSID-FREE DNA VECTORS | GENERATION BIO CO. | 2021-03-04 | — | — | US | disclosed |
| EP-3778585-A1 | QUINOLINE OR QUINAZOLINE COMPOUND AND APPLICATION THEREOF | Haihe Biopharma Co., Ltd. (CN) | 2021-02-17 | — | — | EP | disclosed |
| US-10895569-B2 | Genome-scale T cell activity array and methods of use thereof | YALE UNIVERSITY (US) | 2021-01-19 | — | — | US | disclosed |
| EP-3459935-B1 | UREA DERIVATIVE AS TRK-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2020-12-23 | — | — | EP | disclosed |
| US-20200345743-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2020-11-05 | — | — | US | disclosed |
| EP-2968470-B1 | MODIFIED MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS AND USES THEREOF FOR THE TREATMENT OF DISEASES | MASSACHUSETTS GEN HOSPITAL (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-3225619-B1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2020-10-14 | — | — | EP | disclosed |
| EP-3362792-B1 | GENOME-SCALE T CELL ACTIVITY ARRAY AND METHODS OF USE THEREOF | UNIV YALE (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10751281-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10744202-B2 | Sustained release eye drop formulations | RAMSCOR, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200230051-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. | 2020-07-23 | — | — | US | disclosed |
| WO-2020146433-A1 | POLYMER PROCESS BAGS AND METHODS FOR MANUFACTURING THE SAME | SIO2 MEDICAL PRODUCTS, INC. (US) | 2020-07-16 | — | — | WO | disclosed |
| EP-3679148-A1 | LIPID NANOPARTICLE FORMULATIONS OF NON-VIRAL, CAPSID-FREE DNA VECTORS | Generation Bio Co. (US) | 2020-07-15 | — | — | EP | disclosed |
| US-10709711-B2 | Highly active anti-neoplastic and anti-proliferative agents | G1 THERAPEUTICS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20200206243-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS IN COMBINATION WITH GLUCOCORTICOIDS TO TREAT ADRENAL INSUFFICIENCY | CORCEPT THERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
| CN-107417691-B | Highly effective anti-neoplastic and anti-proliferative agents | G1治疗公司 | 2020-06-26 | — | — | CN | disclosed |
| US-10683278-B2 | Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-16 | — | — | US | disclosed |
| US-10610534-B2 | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency | CORCEPT THERAPEUTICS, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| CN-110709422-A | Multispecific molecules and uses thereof | 埃尔斯塔治疗公司 | 2020-01-17 | — | — | CN | disclosed |
| WO-2019243337-A1 | ORAL COMPOSITIONS COMPRISING METHYLPREDNISOLONE SODIUM SUCCINATE | DOCU-MED LIMITED (CY) | 2019-12-26 | — | — | WO | disclosed |
| US-20190351026-A1 | USES OF MODIFIED MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2019-11-21 | — | — | US | disclosed |
| US-20190307678-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2019-10-10 | — | — | US | disclosed |
| CN-105232463-B | A kind of methylprednisolone immune nano liposome and preparation method thereof with human lung tissue's active targeting | 上海市肺科医院 | 2019-07-19 | — | — | CN | disclosed |
| US-20190192436-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-06-27 | — | — | US | disclosed |
| US-20190125752-A1 | Highly Active Anti-Neoplastic and Anti-Proliferative Agents | G1 THERAPEUTICS, INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-10272034-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-10258668-B2 | Viral vectors for expressing a modified mullerian inhibiting substance (MIS) protein | THE GENERAL HOSPITAL CORPORATION (US) | 2019-04-16 | — | — | US | disclosed |
| WO-2019051289-A1 | LIPID NANOPARTICLE FORMULATIONS OF NON-VIRAL, CAPSID-FREE DNA VECTORS | GENERATION BIO CO. (US) | 2019-03-14 | — | — | WO | disclosed |
| EP-3442972-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20190046725-A1 | MODULAR DOSING ASSEMBLY OF MEDICAL SUBSTANCES | NAYGAUZ MIKAEL (US) | 2019-02-14 | — | — | US | disclosed |
| US-20190046399-A1 | MODULAR DOSING ASSEMBLY OF MEDICAL SUBSTANCES | NAYGAUZ MIKAEL (US) | 2019-02-14 | — | — | US | disclosed |
| US-20190046726-A1 | MODULAR DOSING ASSEMBLY OF MEDICAL SUBSTANCES | NAYGAUZ MIKAEL (US) | 2019-02-14 | — | — | US | disclosed |
| US-20190046400-A1 | MODULAR DOSING ASSEMBLY OF MEDICAL SUBSTANCES | NAYGAUZ MIKAEL (US) | 2019-02-14 | — | — | US | disclosed |
| US-20190046408-A1 | MODULAR DOSING ASSEMBLY OF MEDICAL SUBSTANCES | NAYGAUZ MIKAEL (US) | 2019-02-14 | — | — | US | disclosed |
| US-20190046404-A1 | MODULAR DOSING ASSEMBLY OF MEDICAL SUBSTANCES | NAYGAUZ MIKAEL (US) | 2019-02-14 | — | — | US | disclosed |
| US-20190046403-A1 | MODULAR DOSING ASSEMBLY OF MEDICAL SUBSTANCES | NAYGAUZ MIKAEL (US) | 2019-02-14 | — | — | US | disclosed |
| US-20190046724-A1 | MODULAR DOSING ASSEMBLY OF MEDICAL SUBSTANCES | NAYGAUZ MIKAEL (US) | 2019-02-14 | — | — | US | disclosed |
| US-20190046409-A1 | MODULAR DOSING ASSEMBLY OF MEDICAL SUBSTANCES | NAYGAUZ MIKAEL (US) | 2019-02-14 | — | — | US | disclosed |
| US-10201500-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180318419-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCERS | YALE UNIVERSITY | 2018-11-08 | — | — | US | disclosed |
| US-20180306778-A1 | GENOME-SCALE T CELL ACTIVITY ARRAY AND METHODS OF USE THEREOF | YALE UNIVERSITY | 2018-10-25 | — | — | US | disclosed |
| US-20180289810-A1 | SUSTAINED RELEASE EYE DROP FORMULATIONS | RAMSCOR, INC. (US) | 2018-10-11 | — | — | US | disclosed |
| US-20180265496-A1 | SUBSTITUTED QUINOLONE DERIVATIVES, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR STEREOISOMERS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | JINAN UNIVERSITY (CN) | 2018-09-20 | — | — | US | disclosed |
| EP-3373962-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCERS | Yale University (US) | 2018-09-19 | — | — | EP | disclosed |
| US-10059694-B2 | 2-aminopyrimidine compound and pharmaceutical composition and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2018-08-28 | — | — | US | disclosed |
| EP-3362792-A1 | GENOME-SCALE T CELL ACTIVITY ARRAY AND METHODS OF USE THEREOF | Yale University (US) | 2018-08-22 | — | — | EP | disclosed |
| CN-108251369-A | A kind of immune cell media, cultural method and purposes | 国家卫生计生委科学技术研究所 | 2018-07-06 | — | — | CN | disclosed |
| EP-3339294-A1 | PHARMACEUTICAL COMPOSITION AND APPLICATION REPLACING QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER | Jinan University (CN) | 2018-06-27 | — | — | EP | disclosed |
| US-9993558-B2 | Sustained release eye drop formulations | RAMSCOR, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| CN-105073138-B | Pharmaceutical preparation comprising insoluble corticosteroid and soluble corticosteroid | 塞姆努尔药物公司 | 2018-06-05 | — | — | CN | disclosed |
| WO-2018081091-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| US-20180078565-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS IN COMBINATION WITH GLUCOCORTICOIDS TO TREAT ADRENAL INSUFFICIENCY | CORCEPT THERAPEUTICS, INC. | 2018-03-22 | — | — | US | disclosed |
| EP-3277281-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS IN COMBINATION WITH GLUCOCORTICOIDS TO TREAT ADRENAL INSUFFICIENCY | Corcept Therapeutics, Inc. (US) | 2018-02-07 | — | — | EP | disclosed |
| US-20180015096-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2018-01-18 | — | — | US | disclosed |
| CN-107592807-A | Cyclic olefin polymer container with damage resistant and anlistatig coating | SIO2医药产品公司 | 2018-01-16 | — | — | CN | disclosed |
| EP-3266450-A1 | NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF | Abraxis BioScience, LLC (US) | 2018-01-10 | — | — | EP | disclosed |
| CN-107417691-A | Efficient anti-superfluous raw agent and anti-proliferative agent | G1治疗公司 | 2017-12-01 | — | — | CN | disclosed |
| WO-2017177955-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2017-10-19 | — | — | WO | disclosed |
| US-20170283398-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-10-05 | — | — | US | disclosed |
| EP-3225619-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Institute Of Materia Medica Chinese Academy of Sciences (CN) | 2017-10-04 | — | — | EP | disclosed |
| WO-2017083354-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCERS | YALE UNIVERSITY (US) | 2017-05-18 | — | — | WO | disclosed |
| CN-102743392-B | methylprednisolone sodium succinate composition | 天津金耀集团有限公司 | 2017-05-10 | — | — | CN | disclosed |
| WO-2017066172-A1 | GENOME-SCALE T CELL ACTIVITY ARRAY AND METHODS OF USE THEREOF | YALE UNIVERSITY (US) | 2017-04-20 | — | — | WO | disclosed |
| US-9498439-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160310499-A1 | Highly Active Anti-Neoplastic and Anti-Proliferative Agents | G1 THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
| US-9468607-B2 | Ligand directed toroidal nanoparticles for therapy and diagnostic imaging | WASHINGTON UNIVERSITY (US) | 2016-10-18 | — | — | US | disclosed |
| WO-2016160969-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS IN COMBINATION WITH GLUCOCORTICOIDS TO TREAT ADRENAL INSUFFICIENCY | CORCEPT THERAPEUTICS, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20160279060-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-29 | — | — | US | disclosed |
| US-9446150-B2 | Particles for imaging | WASHINGTON UNIVERSITY (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160243028-A1 | Auris Formulations for Treating Otic Diseases and Conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2016-08-25 | — | — | US | disclosed |
| US-20160228514-A1 | USES OF MODIFIED MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160228357-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTONOMY, INC. | 2016-08-11 | — | — | US | disclosed |
| EP-3046582-A1 | USES OF MODIFIED MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | The General Hospital Corporation (US) | 2016-07-27 | — | — | EP | disclosed |
| EP-2286828-B1 | IMPROVING AGENT FOR NEUROPATHIC PAIN | UNIV NAGOYA NAT UNIV CORP (JP) | 2016-05-18 | — | — | EP | disclosed |
| US-20160095902-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTONOMY, INC. | 2016-04-07 | — | — | US | disclosed |
| CN-105407723-A | Highly effective anti-neoplastic and anti-proliferative agents | G1 THERAPEUTICS INC | 2016-03-16 | — | — | CN | disclosed |
| US-20160039898-A1 | MODIFIED MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS AND USES THEREOF FOR THE TREATMENT OF DISEASES | MASSACHUSETTS EYE AND EAR INFIRMARY | 2016-02-11 | — | — | US | disclosed |
| EP-2968470-A1 | MODIFIED MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS AND USES THEREOF FOR THE TREATMENT OF DISEASES | The General Hospital Corporation (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970330-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2967050-A2 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| CN-105232463-A | Methylprednisolone-immune nano-liposome with human lung tissue active targeting performance and preparation method thereof | SHANGHAI PULMONARY HOSPITAL | 2016-01-13 | — | — | CN | disclosed |
| EP-2958907-A1 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | Novartis AG (CH) | 2015-12-30 | — | — | EP | disclosed |
| CN-105073138-A | Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid | SEMNUR PHARMACEUTICALS INC | 2015-11-18 | — | — | CN | disclosed |
| US-20150297608-A1 | Tricyclic Lactams for Use as Anti-Neoplastic and Anti-Proliferative Agents | G1 THERAPEUTICS, INC. (US) | 2015-10-22 | — | — | US | disclosed |
| WO-2015161288-A1 | TRICYCLIC LACTAMS FOR USE AS ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
| US-20150273066-A1 | CONVENIENTLY IMPLANTABLE SUSTAINED RELEASE DRUG COMPOSITIONS | RAMSCOR INC (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150148317-A1 | SPINAL CORD INJURY, INFLAMMATION, AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS | INVIVO THERAPEUTICS CORPORATION (US) | 2015-05-28 | — | — | US | disclosed |
| WO-2015074083-A1 | METHODS FOR DIAGNOSING T CELL-MEDIATED INFLAMMATION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-05-21 | — | — | WO | disclosed |
| EP-2858982-A1 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES | AbbVie Inc. (US) | 2015-04-15 | — | — | EP | disclosed |
| US-20150093434-A1 | LIPOSOMAL COMPOSITIONS OF GLUCOCORTICOID AND GLUCOCORTICOID DERIVATIVES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERSUSALEM (IL) | 2015-04-02 | — | — | US | disclosed |
| WO-2015041718-A1 | USES OF MODIFIED MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2015-03-26 | — | — | WO | disclosed |
| US-8932627-B2 | Liposomal compositions of glucocorticoid and glucocorticoid derivatives | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2015-01-13 | — | — | US | disclosed |
| US-20140335108-A1 | UTILITY OF INSULIN-LIKE 6 (INSL6) FOR THE TREATMENT OF AUTOIMMUNE DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-13 | — | — | US | disclosed |
| EP-2476444-B1 | Medical device with intrapore films | COVIDIEN LP (US) | 2014-11-05 | — | — | EP | disclosed |
| WO-2014164981-A1 | MODIFIED MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS AND USES THEREOF FOR THE TREATMENT OF DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2014-10-09 | — | — | WO | disclosed |
| US-8841317-B2 | Noscapine and analogs and methods related thereto | EMORY UNIVERSITY (US) | 2014-09-23 | — | — | US | disclosed |
| WO-2014144740-A2 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014139324-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140271460-A1 | Highly Active Anti-Neoplastic and Anti-Proliferative Agents | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014130310-A1 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NOVARTIS AG (CH) | 2014-08-28 | — | — | WO | disclosed |
| CN-102898661-B | Polyethylene glycol hydrogel for orthotopic injection and preparation method thereof | UNIV ZHEJIANG | 2014-01-08 | — | — | CN | disclosed |
| CN-103492590-A | Circulating biomarkers | CARIS LIFE SCIENCES LUXEMBOURG HOLDINGS S A R L | 2014-01-01 | — | — | CN | disclosed |
| WO-2013185284-A1 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES | ABBOTT LABORATORIES (US) | 2013-12-19 | — | — | WO | disclosed |
| US-20130324481-A1 | SUSTAINED RELEASE EYE DROP FORMULATIONS | RAMSCOR, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20130324509-A1 | SPINAL CORD INJURY, INFLAMMATION, AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS | INVIVO THERAPEUTICS CORPORATION (US) | 2013-12-05 | — | — | US | disclosed |
| US-20130324500-A1 | SPINAL CORD INJURY, INFLAMMATION AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS | INVIVO THERAPEUTICS CORPORATION (US) | 2013-12-05 | — | — | US | disclosed |
| EP-1023050-B1 | NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF | ABRAXIS BIOSCIENCE LLC (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2013090318-A1 | UTILITY OF INSULIN-LIKE 6 (INSL6) FOR THE TREATMENT OF AUTOIMMUNE DISEASES | TRUSTEES OF BOSTON UNIVERSITY (US) | 2013-06-20 | — | — | WO | disclosed |
| US-20130122100-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | THE WASHINGTON UNIVERSITY (US) | 2013-05-16 | — | — | US | disclosed |
| EP-1910362-B9 | IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS | SIRTRIS PHARMACEUTICALS INC (US) | 2013-02-20 | — | — | EP | disclosed |
| CN-102898661-A | Polyethylene glycol hydrogel for orthotopic injection and preparation method thereof | UNIV ZHEJIANG | 2013-01-30 | — | — | CN | disclosed |
| CN-102781470-A | Il-17 binding proteins | ABBOTT LAB | 2012-11-14 | — | — | CN | disclosed |
| CN-102770451-A | Dual variable domain immunoglobulins and uses thereof | ABBOTT LAB | 2012-11-07 | — | — | CN | disclosed |
| CN-102743392-A | Methylprednisolone sodium succinate composition | TIANJIN JINYAO GROUP CO LTD | 2012-10-24 | — | — | CN | disclosed |
| EP-1910362-B1 | IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS | SIRTRIS PHARMACEUTICALS INC (US) | 2012-10-17 | — | — | EP | disclosed |
| CN-102741423-A | Dual variable domain immunoglobulins and uses thereof | ABBOTT LAB | 2012-10-17 | — | — | CN | disclosed |
| CN-102666875-A | Dual variable domain immunoglobulins and uses thereof | ABBOTT LAB | 2012-09-12 | — | — | CN | disclosed |
| CN-102655880-A | IL-1 binding proteins | ABBOTT LAB | 2012-09-05 | — | — | CN | disclosed |
| CN-102612524-A | Dual variable domain immunoglobulins and uses thereof | ABBOTT LAB | 2012-07-25 | — | — | CN | disclosed |
| EP-2476444-A2 | Medical device with intrapore films | Tyco Healthcare Group LP (US) | 2012-07-18 | — | — | EP | disclosed |
| EP-2468752-A1 | Thiazolopyridine derivatives as sirtuin-modulators | Sirtris Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| US-8188083-B2 | Triazolopyridazines | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| CN-102369217-A | Il-1 binding proteins | ABBOTT LAB | 2012-03-07 | — | — | CN | disclosed |
| US-20120053199-A1 | NOSCAPINE AND ANALOGS AND METHODS RELATED THERETO | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2011049960-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SINONASAL DISORDERS | OTONOMY, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011050206-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SINONASAL DISORDERS | OTONOMY, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-7897645-B2 | Herpesvirus-derived therapeutic agent for pain | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-01 | — | — | US | disclosed |
| EP-2286828-A1 | AMELIORATING AGENT FOR NEUROGENIC PAIN | National University Corporation Nagoya University (JP) | 2011-02-23 | — | — | EP | disclosed |
| EP-1908467-B1 | AGENT FOR TREATING HERPESVIRUS-DERIVED PAIN | JUNTENDO EDUCATIONAL FOUNDATION (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20100310544-A1 | COMPOSITION COMPRISING CALCIUM IONS AND AT LEAST ONE PROTEOLYTIC ENZYME FOR USE IN THE IN VITRO AND IN VIVO REGENERATION OF CUTANEOUS AND CONNECTIVE TISSUES | MEDEVICE S.P.A. (IT) | 2010-12-09 | — | — | US | disclosed |
| CN-101048138-B | Use of liposomal glucocorticoids for treating inflammatory states | YISSUM RES DEV CO | 2010-12-08 | — | — | CN | disclosed |
| US-20100297019-A1 | PARTICLES FOR IMAGING | THE WASHINGTON UNIVERSITY (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100297007-A1 | LIGAND DIRECTED TOROIDAL NANOPARTICLES FOR THERAPY AND DIAGNOSTIC IMAGING | THE WASHINGTON UNIVERSITY (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2227083-A1 | COMPOSITION COMPRISING CALCIUM IONS AND AT LEAST ONE PROTEOLYTIC ENZYME FOR USE IN THE IN VITRO AND IN VIVO REGENERATION OF CUTANEOUS AND CONNECTIVE TISSUES | Medevice S.P.A. (IT) | 2010-09-15 | — | — | EP | disclosed |
| US-20100196481-A1 | SPINAL CORD INJURY, INFLAMMATION, AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS | INVIVO THERAPEUTICS CORPORATION (US) | 2010-08-05 | — | — | US | disclosed |
| US-7744920-B2 | Glucocoricoid is an amphipathic weak acid or base such as methylprednisolone sodium hemisuccinate encapsulated in a liposome; treating rheumatoid arthritis or other autoimmune disease, provided they are not neurodegenerative disorders | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2010-06-29 | — | — | US | disclosed |
| US-7744920-B2 | Glucocoricoid is an amphipathic weak acid or base such as methylprednisolone sodium hemisuccinate encapsulated in a liposome; treating rheumatoid arthritis or other autoimmune disease, provided they are not neurodegenerative disorders | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2010-06-29 | — | — | US | disclosed |
| EP-2170337-A1 | NOVEL TRIAZOLOPYRIDAZINES | Abbott Laboratories (US) | 2010-04-07 | — | — | EP | disclosed |
| EP-1611893-B1 | REMEDY FOR NERVE DAMAGE | SEIKAGAKU KOGYO CO LTD (JP) | 2010-01-20 | — | — | EP | disclosed |
| EP-2139329-A1 | NOVEL IMIDAZO BASED HETEROCYCLES | Abbott Laboratories (US) | 2010-01-06 | — | — | EP | disclosed |
| US-20090270402-A1 | Novel triazolopyridazines | ABBVIE INC. | 2009-10-29 | — | — | US | disclosed |
| EP-2080511-A2 | Active agent delivery systems and methods for protecting and administering active agents | Shire LLC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090149532-A1 | HERPESVIRUS-DERIVED THERAPEUTIC AGENT FOR PAIN | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-06-11 | — | — | US | disclosed |
| WO-2009069022-A1 | COMPOSITION COMPRISING CALCIUM IONS AND AT LEAST ONE PROTEOLYTIC ENZYME FOR USE IN THE IN VITRO AND IN VIVO REGENERATION OF CUTANEOUS AND CONNECTIVE TISSUES | MEDEVICE S.P.A. (IT) | 2009-06-04 | — | — | WO | disclosed |
| EP-1160018-B1 | Method and apparatus for fine particle formation | SIEVERS ROBERT E (US) | 2009-04-29 | — | — | EP | disclosed |
| CN-101407471-A | Compound capable of binding S1P receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO (JP) | 2009-04-15 | — | — | CN | disclosed |
| US-7511026-B2 | Therapeutic agent for nerve damage | SEIKAGAKU CORPORATION (JP) | 2009-03-31 | — | — | US | disclosed |
| US-20090042911-A1 | Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-YL](3R,5S)-3, 5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of P450 isoenzyme 3A4 | PEARS JOHN S | 2009-02-12 | — | — | US | disclosed |
| WO-2009005675-A1 | NOVEL TRIAZOLOPYRIDAZINES | ABBOTT LABORATORIES (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20080249305-A1 | Novel imidazole based heterocycles | ABBOTT LABORATORIES | 2008-10-09 | — | — | US | disclosed |
| US-20080242862-A1 | Novel imidazo based heterocycles | ABBOTT LABORATORIES | 2008-10-02 | — | — | US | disclosed |
| WO-2008118485-A1 | NOVEL IMIDAZO BASED HETEROCYCLES | ABBOTT LABORATORIES (US) | 2008-10-02 | — | — | WO | disclosed |
| EP-1908467-A1 | HERPESVIRUS-DERIVED THERAPEUTIC AGENT FOR PAIN | Juntendo Educational Foundation (JP) | 2008-04-09 | — | — | EP | disclosed |
| US-20080066739-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | disclosed |
| US-20080058294-A1 | Glucocorticoid encapsulated within liposome; multiple sclerosis, anticancer agents | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2008-03-06 | — | — | US | disclosed |
| US-20080003276-A1 | Glucocoricoid is an amphipathic weak acid or base such as methylprednisolone sodium hemisuccinate encapsulated in a liposome; treating rheumatoid arthritis or other autoimmune disease, provided they are not neurodegenerative disorders | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2008-01-03 | — | — | US | disclosed |
| US-20080003276-A1 | Glucocoricoid is an amphipathic weak acid or base such as methylprednisolone sodium hemisuccinate encapsulated in a liposome; treating rheumatoid arthritis or other autoimmune disease, provided they are not neurodegenerative disorders | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2008-01-03 | — | — | US | disclosed |
| CN-101048138-A | Use of liposomal glucocorticoids for treating inflammatory states | YISSUM RES DEV CO (IL) | 2007-10-03 | — | — | CN | disclosed |
| EP-1793804-A2 | USE OF LIPOSOMAL GLUCOCORTICOIDS FOR TREATING INFLAMMATORY STATES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-06-13 | — | — | EP | disclosed |
| EP-1793804-A2 | USE OF LIPOSOMAL GLUCOCORTICOIDS FOR TREATING INFLAMMATORY STATES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-06-13 | — | — | EP | disclosed |
| EP-1791525-A1 | LIPOSOMAL COMPOSITIONS OF GLUCOCORTICOID AND GLUCOCORTICOID DERIVATIVES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-06-06 | — | — | EP | disclosed |
| US-20070111945-A1 | USE OF CORTICOTROPH-DERIVED GLYCOPROTEIN HORMONE TO TREAT INFLAMMATION AND POTENTIATE GLUCOCORTICOID ACTION | ZYMOGENETICS, INC. | 2007-05-17 | — | — | US | disclosed |
| EP-1512008-A4 | USE OF CORTICOTROPH-DERIVED GLYCOPROTEIN HORMONE TO TREAT INFLAMMATION AND POTENTIATE GLUCOCORTICOID ACTION | ZYMOGENETICS INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20070010446-A1 | METHODS FOR TREATING INFLAMMATION USING THYROID STIMULATING HORMONE | ZYMOGENETICS, INC. | 2007-01-11 | — | — | US | disclosed |
| EP-1706138-A2 | METHODS FOR TREATING INFLAMMATION USING THYROID STIMULATING HORMONE | ZymoGenetics, Inc. (US) | 2006-10-04 | — | — | EP | disclosed |
| WO-2006094246-A2 | N-ARYLMETHYL BENZAMIDE SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006094210-A2 | TETRAHYDROQUINOXALINONE SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006027786-A8 | USE OF LIPOSOMAL GLUCOCORTICOIDS FOR TREATING INFLAMMATORY STATES | YISSUM RES DEV CO (IL) | 2006-08-31 | — | — | WO | disclosed |
| US-20060135439-A1 | Remedy for nerve damage | NOVELIS CORPORATION | 2006-06-22 | — | — | US | disclosed |
| WO-2006027786-A3 | USE OF LIPOSOMAL GLUCOCORTICOIDS FOR TREATING INFLAMMATORY STATES | YISSUM RES DEV CO (IL) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006027787-A1 | LIPOSOMAL COMPOSITIONS OF GLUCOCORTICOID AND GLUCOCORTICOID DERIVATIVES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006027786-A2 | USE OF LIPOSOMAL GLUCOCORTICOIDS FOR TREATING INFLAMMATORY STATES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006027786-A2 | USE OF LIPOSOMAL GLUCOCORTICOIDS FOR TREATING INFLAMMATORY STATES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-03-16 | — | — | WO | disclosed |
| US-20060040969-A1 | Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of P450 isoenzyme 3A4 | ASTRAZENECA AB | 2006-02-23 | — | — | US | disclosed |
| EP-1611893-A1 | REMEDY FOR NERVE DAMAGE | SEIKAGAKU CORPORATION (JP) | 2006-01-04 | — | — | EP | disclosed |
| US-6982157-B1 | Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methylsulfonyl)amino] pyrimidin-5-yl] (3r,5s) -3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3A4 | ASTRAZENECA AB (GB) | 2006-01-03 | — | — | US | disclosed |
| US-20050171017-A1 | Methods for treating inflammation using thyroid stimulating hormone | ZYMOGENETICS, INC. | 2005-08-04 | — | — | US | disclosed |
| WO-2005056046-A2 | METHODS FOR TREATING INFLAMMATION USING THYROID STIMULATING HORMONE | ZYMOGENETICS, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| CN-1612936-A | Identification, monitoring and treatment of diseases and identification of biological states using gene expression profiles | SOURCE PRECISION MEDICINE INC (US) | 2005-05-04 | — | — | CN | disclosed |
| EP-1512008-A1 | USE OF CORTICOTROPH-DERIVED GLYCOPROTEIN HORMONE TO TREAT INFLAMMATION AND POTENTIATE GLUCOCORTICOID ACTION | ZymoGenetics, Inc. (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040235794-A1 | Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1185274-B1 | DRUG COMBINATIONS COMPRISING (E)-7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]PYRIMIDIN-5-YL](3R,5S)-3,5-DIHYDROXYHEPT-6-ENOIC ACID AND AN INHIBITOR, INDUCER OR SUBSTRATE OF P450 ISOENZYME 3A4 | ASTRAZENECA AB (SE) | 2004-11-17 | — | — | EP | disclosed |
| US-20040138113-A1 | Use of corticotroph-derived glycoprotein hormone to treat inflammation and potentiate glucocorticoid action | ZYMOGENETICS, INC. | 2004-07-15 | — | — | US | disclosed |
| EP-1424078-A1 | REMEDIES FOR RESPIRATORY DISEASES COMPRISING SPHINGOSINE-1-PHOSPHATE RECEPTOR CONTROLLER | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003104807-A1 | USE OF CORTICOTROPH-DERIVED GLYCOPROTEIN HORMONE TO TREAT INFLAMMATION AND POTENTIATE GLUCOCORTICOID ACTION | ZYMOGENETICS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| EP-1017274-B1 | COMPOSITIONS, METHODS AND DEVICES FOR MAINTAINING AN ORGAN | HASSANEIN WALEED H (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20030023070-A1 | Attractin-like polynucleotides, polypeptides, and antibodies | HUMAN GENOME SCIENCES, INC. (US) | 2003-01-30 | — | — | US | disclosed |
| EP-1244701-A1 | TRANSFERRIN POLYNUCLEOTIDES, POLYPEPTIDES, AND ANTIBODIES | Human Genome Sciences, Inc. (US) | 2002-10-02 | — | — | EP | disclosed |
| EP-0705298-B1 | ALBUMIN BASED HYDROGEL | BIOARTIFICIAL GEL TECHNOLOGIES INC (CA) | 2002-03-27 | — | — | EP | disclosed |
| EP-0677332-B1 | Methods and apparatus for fine particle formation | SIEVERS ROBERT E (US) | 2002-02-27 | — | — | EP | disclosed |
| US-20020018815-A1 | Methods and apparatus for fine particle formation | UNIVERSITY TECHNOLOGY CORPORATION | 2002-02-14 | — | — | US | disclosed |
| EP-1160018-A2 | Method and apparatus for fine particle formation | Sievers, Robert, E. (US) | 2001-12-05 | — | — | EP | disclosed |
| US-20010041676-A1 | Glycosides and orthoester glycosides of glucocorticoids and uses thereof | STRAKAN LIMITED (BM) | 2001-11-15 | — | — | US | disclosed |
| WO-2001051057-A2 | GLYCOSIDES AND ORTHOESTER GLYCOSIDES OF GLUCOCORTICOIDS AND USES THEREOF | STRAKAN LIMITED (BM) | 2001-07-19 | — | — | WO | disclosed |
| WO-2001046254-A1 | TRANSFERRIN POLYNUCLEOTIDES, POLYPEPTIDES, AND ANTIBODIES | HUMAN GENOME SCIENCES, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| US-6095134-A | Methods and apparatus for fine particle formation | THE BOARD OF REGENTS OF THE UNIVERSITY OF CO (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| WO-1999000113-A9 | NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF | VIVORX PHARMACEUTICALS INC (US) | 1999-04-08 | — | — | WO | disclosed |
| EP-0858325-A1 | STABLE FREEZE-DRIED PHARMACEUTICAL FORMULATION | SANOFI (FR) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| US-5639441-A | DISSOLVING SUBSTANCE TO FORM SOLUTION, MIXING WITH FLUID WHICH FORMS GAS ON RAPID DEPRESSURIZATION, DEPRESSURIZATION | BOARD OF REGENTS OF UNIVERSITY OF COLORADO (US) | 1997-06-17 | — | — | US | disclosed |
| WO-1997017064-A1 | STABLE FREEZE-DRIED PHARMACEUTICAL FORMULATION | SANOFI (FR) | 1997-05-15 | — | — | WO | disclosed |
| EP-0677332-A2 | Methods and apparatus for fine particle formation | Sievers, Robert, E. (US) | 1995-10-18 | — | — | EP | disclosed |
| EP-0274431-B1 | Drug delivery compositions and methods | QUIXOTE CORP (US) | 1994-05-04 | — | — | EP | disclosed |
| US-5250711-A | Amine salts of alkane-1,n-dicarboxylic acid mono-(2-sulfato-ethyl) amides | THE UPJOHN COMPANY (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0374166-B1 | AMINE SALTS OF ALKANE-1,N-DICARBOXYLIC ACID MONO-(2-SULFATO-ETHYL)AMIDES | THE UPJOHN COMPANY (US) | 1993-01-07 | — | — | EP | disclosed |
| EP-0374166-A1 | AMINE SALTS OF ALKANE-1,n-DICARBOXYLIC ACID MONO-(2-SULFATO-ETHYL)AMIDES. | UPJOHN CO (US) | 1990-06-27 | — | — | EP | disclosed |
| WO-1989000558-A1 | AMINE SALTS OF ALKANE-1,n-DICARBOXYLIC ACID MONO-(2-SULFATO-ETHYL)AMIDES | THE UPJOHN COMPANY (US) | 1989-01-26 | — | — | WO | disclosed |
| US-4758431-A | Extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | THOMAS JEFFERSON UNIVERSITY (US) | 1988-07-19 | — | — | US | disclosed |
| EP-0274431-A2 | Drug delivery compositions and methods | QUIXOTE CORPORATION (US) | 1988-07-13 | — | — | EP | disclosed |
| EP-0215313-A2 | Emulsion compositions for the parenteral and/or oral administration of sparingly water soluble ionizable hydrophobic drugs | AMERICAN CYANAMID COMPANY (US) | 1987-03-25 | — | — | EP | disclosed |
| US-4393863-A | Extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | THOMAS JEFFERSON UNIVERSITY (US) | 1983-07-19 | — | — | US | disclosed |
| US-4378797-A | Extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | THOMAS JEFFERSON UNIVERSITY (US) | 1983-04-05 | — | — | US | disclosed |
| US-4378797-A | Extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | THOMAS JEFFERSON UNIVERSITY (US) | 1983-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (49 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180265496-A1 | SUBSTITUTED QUINOLONE DERIVATIVES, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR STEREOISOMERS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | NRAS, AXL, ABL1 | HIF1A 2004/4885HSD17B10 3233/4885NR3C1 916/4885 |
| US-20180078565-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS IN COMBINATION WITH GLUCOCORTICOIDS TO TREAT ADRENAL INSUFFICIENCY | NR3C2, MC2R, NR3C1 | HIF1A 3026/4885HSD17B10 289/4885NR3C1 3/4885 |
| US-20180015096-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | MKI67, PCNA, HRAS | HIF1A 1282/4885HSD17B10 2840/4885NR3C1 2221/4885 |
| US-10059694-B2 | 2-aminopyrimidine compound and pharmaceutical composition and use thereof | EGFR, ERBB2, IGF1R | HIF1A 3076/4885HSD17B10 4486/4885NR3C1 3162/4885 |
| US-11890260-B2 | Compositions for treating acne and dermatological conditions | COQ8A, ATP5ME, AGK | HIF1A 1441/4885HSD17B10 271/4885NR3C1 3071/4885 |
| US-20230025960-A1 | TOPICAL COMPOSITIONS CONTAINING ROSE OIL AND CANNABIDIOL AND METHODS OF MAKING AND USING THE SAME | RXRG, CNR2, CUTA | HIF1A 1331/4885HSD17B10 802/4885NR3C1 2774/4885 |
| US-20210169759-A1 | TOPICAL COMPOSITIONS CONTAINING ROSE OIL AND CANNABIDIOL AND METHODS OF MAKING AND USING THE SAME | RXRG, CNR2, CUTA | HIF1A 1331/4885HSD17B10 802/4885NR3C1 2774/4885 |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | MKI67, PCNA, HRAS | HIF1A 1282/4885HSD17B10 2840/4885NR3C1 2221/4885 |
| US-20190125752-A1 | Highly Active Anti-Neoplastic and Anti-Proliferative Agents | MKI67, PCNA, HRAS | HIF1A 1282/4885HSD17B10 2840/4885NR3C1 2221/4885 |
| US-20040235794-A1 | Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller | S1PR1, S1PR5, S1PR3 | HIF1A 1217/4885HSD17B10 3473/4885NR3C1 369/4885 |
| US-20090270402-A1 | Novel triazolopyridazines | MAP3K5, MAP3K1, MAP3K2 | HIF1A 906/4885HSD17B10 1885/4885NR3C1 697/4885 |
| US-20160279060-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | FAP, PNP, TYMP | HIF1A 579/4885HSD17B10 1237/4885NR3C1 3318/4885 |
| US-20090149532-A1 | HERPESVIRUS-DERIVED THERAPEUTIC AGENT FOR PAIN | RPL35, DDOST, HSPB1 | HIF1A 42/4885HSD17B10 1689/4885NR3C1 1885/4885 |
| US-20200345743-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | MKI67, PCNA, HRAS | HIF1A 1282/4885HSD17B10 2840/4885NR3C1 2221/4885 |
| US-20160243028-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTC, AQP4, SLC26A4 | HIF1A 283/4885HSD17B10 4508/4885NR3C1 2039/4885 |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | HIF1A 283/4885HSD17B10 4508/4885NR3C1 2039/4885 |
| US-11123286-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | HIF1A 283/4885HSD17B10 4508/4885NR3C1 2039/4885 |
| US-20190307678-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | HIF1A 283/4885HSD17B10 4508/4885NR3C1 2039/4885 |
| US-20200230051-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | HIF1A 283/4885HSD17B10 4508/4885NR3C1 2039/4885 |
| US-20130122100-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | PHOSPHO1, PTDSS1, SMPD3 | HIF1A 1126/4885HSD17B10 3011/4885NR3C1 4153/4885 |
| US-20190192436-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | FAP, PNP, TYMP | HIF1A 579/4885HSD17B10 1237/4885NR3C1 3318/4885 |
| US-10751281-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | HIF1A 283/4885HSD17B10 4508/4885NR3C1 2039/4885 |
| US-10683278-B2 | Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof | NRAS, AXL, ABL1 | HIF1A 2004/4885HSD17B10 3233/4885NR3C1 916/4885 |
| US-20210361591-A1 | COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS | COQ8A, ATP5ME, AGK | HIF1A 1441/4885HSD17B10 271/4885NR3C1 3071/4885 |
| US-20160095902-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTC, AQP4, SLC26A4 | HIF1A 283/4885HSD17B10 4508/4885NR3C1 2039/4885 |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTC, AQP4, SLC26A4 | HIF1A 283/4885HSD17B10 4508/4885NR3C1 2039/4885 |
| US-20140271460-A1 | Highly Active Anti-Neoplastic and Anti-Proliferative Agents | MKI67, PCNA, HRAS | HIF1A 1282/4885HSD17B10 2840/4885NR3C1 2221/4885 |
| US-20120053199-A1 | NOSCAPINE AND ANALOGS AND METHODS RELATED THERETO | NOS2, NOS1, NOS3 | HIF1A 273/4885HSD17B10 3805/4885NR3C1 335/4885 |
| US-20200206243-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS IN COMBINATION WITH GLUCOCORTICOIDS TO TREAT ADRENAL INSUFFICIENCY | CRH, MC2R, NR3C2 | HIF1A 2492/4885HSD17B10 213/4885NR3C1 6/4885 |
| US-11141379-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | FAP, PNP, TYMP | HIF1A 579/4885HSD17B10 1237/4885NR3C1 3318/4885 |
| US-10709711-B2 | Highly active anti-neoplastic and anti-proliferative agents | MKI67, PCNA, HRAS | HIF1A 1282/4885HSD17B10 2840/4885NR3C1 2221/4885 |
| US-20080242862-A1 | Novel imidazo based heterocycles | CDK4, CDK2, MAP3K15 | HIF1A 1567/4885HSD17B10 3102/4885NR3C1 743/4885 |
| US-20210059953-A1 | LIPID NANOPARTICLE FORMULATIONS OF NON-VIRAL, CAPSID-FREE DNA VECTORS | HDLBP, POLN, NPC1 | HIF1A 2717/4885HSD17B10 1175/4885NR3C1 3508/4885 |
| US-10272034-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | HIF1A 283/4885HSD17B10 4508/4885NR3C1 2039/4885 |
| US-20160228357-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTC, AQP4, SLC26A4 | HIF1A 283/4885HSD17B10 4508/4885NR3C1 2039/4885 |
| US-20170283398-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | EGFR, ERBB2, IGF1R | HIF1A 3076/4885HSD17B10 4486/4885NR3C1 3162/4885 |
| US-20210077400-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | FAP, PNP, TYMP | HIF1A 579/4885HSD17B10 1237/4885NR3C1 3318/4885 |
| US-20210078972-A1 | QUINOLINE OR QUINAZOLINE COMPOUND AND APPLICATION THEREOF | AXL, MKI67, NRAS | HIF1A 1267/4885HSD17B10 2936/4885NR3C1 2409/4885 |
| US-20240130980-A1 | COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS | COQ8A, ATP5ME, AGK | HIF1A 1441/4885HSD17B10 271/4885NR3C1 3071/4885 |
| US-10201500-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | FAP, PNP, TYMP | HIF1A 579/4885HSD17B10 1237/4885NR3C1 3318/4885 |
| US-11872313-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | FAP, PNP, TYMP | HIF1A 579/4885HSD17B10 1237/4885NR3C1 3318/4885 |
| US-20160310499-A1 | Highly Active Anti-Neoplastic and Anti-Proliferative Agents | MKI67, PCNA, HRAS | HIF1A 1282/4885HSD17B10 2840/4885NR3C1 2221/4885 |
| US-20240156835-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS IN COMBINATION WITH GLUCOCORTICOIDS TO TREAT ADRENAL INSUFFICIENCY | NR3C2, MC2R, NR3C1 | HIF1A 3026/4885HSD17B10 289/4885NR3C1 3/4885 |
| US-20080249305-A1 | Novel imidazole based heterocycles | MAP3K5, MAP3K15, MAP3K20 | HIF1A 1746/4885HSD17B10 3441/4885NR3C1 921/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | HIF1A 283/4885HSD17B10 4508/4885NR3C1 2039/4885 |
| US-10610534-B2 | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency | NR3C2, MC2R, NR3C1 | HIF1A 3026/4885HSD17B10 289/4885NR3C1 3/4885 |
| US-20150297608-A1 | Tricyclic Lactams for Use as Anti-Neoplastic and Anti-Proliferative Agents | PCNA, TOP2A, CCNI | HIF1A 3107/4885HSD17B10 1967/4885NR3C1 4414/4885 |
| US-11890289-B2 | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency | NR3C2, MC2R, NR3C1 | HIF1A 3026/4885HSD17B10 289/4885NR3C1 3/4885 |
| US-20010041676-A1 | Glycosides and orthoester glycosides of glucocorticoids and uses thereof | NR3C1, NR3C2, SERPINA6 | HIF1A 3621/4885HSD17B10 276/4885NR3C1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.